9 Transactions with related companies and persons
9.1 Compensation paid to members of the Board of Directors and to members of the Group Executive Board
CHF 1 000 | 01.01.-31.12.2023 | 01.01.-31.12.2022 | ||||||
Board of Directors | Group Executive Board | Board of Directors | Group Executive Board | |||||
Fixed compensation | 721 | 764 | 613 | 1 018 | ||||
– in cash | 531 | 764 | 613 | 1 018 | ||||
– in shares 1) | 190 | – | – | – | ||||
Non-monetary benefit from voluntary stock purchase programs 2) | 14 | – | 34 | 63 | ||||
Short-term variable compensation | – | 611 | 147 | 915 | ||||
– in cash | – | 611 | – | 632 | ||||
– in shares 3) | – | – | 147 | 283 | ||||
– in shares with vesting period 4) | – | 665 | – | 1 136 | ||||
Long-term variable compensation | – | – 65 | – | – 110 | ||||
– in shares 5) | – | – 65 | – | – 110 | ||||
Total | 735 | 1 975 | 794 | 3 022 | ||||
1) The allocation is made in freely available shares
2) The purchase/allocation is made in 3 years blocked and discounted shares
3) The allocation is made in 4 years restricted shares
4) The allocation is made in 4 years restricted shares with one-year service period and right of redemption (taking into account the service/vesting period in accordance with IFRS 2)
5) Members of the Group Executive Board partially participate in an employee stock ownership plan in connection with the asset management mandate of BB Biotech AG. Within the scope of these plans, some of the members of the Group Executive Board are entitled to receive a maximum number of shares in BB Biotech AG. The actual number of shares awarded depends on various conditions. Awarded shares are subject to a three-year vesting period beginning on the date of grant. In addition, the actual number of shares distributed will depend on the achievement of certain performance targets over the subsequent three fiscal years in connection with the respective investment mandates. The cost of this employee program is recognized as long-term variable compensation.
The amounts listed for fixed and variable compensation also include any employer contributions to statutory or regulatory social security schemes.
In the financial years 2023 and 2022, no compensation was paid to related parties of members of the Board of Directors and Group Executive Board, nor to former members of the Board of Directors.
9.2 Transactions with related companies and persons
As of December 31, 2023 and 2022, there were neither receivables nor liabilities to related companies and persons.